TRI's mission is to identify, help create and support the development of new therapeutic drug discovery opportunities worldwide. We do this by investing in pharmaceutical technology and product concepts, and highly effective management teams that can turn ideas into reality. As a strategic investor, our primary focus is on medium to longer term returns in the form of products and technologies that will also yield capital gains for the institutions we work with. In general, we will make minority investments and assume a passive role in management. However, we are also interested in forging active, collaborative partnerships to create synergies with Takeda's considerable R&D resources.

TRI is based in Palo Alto, California and is actively seeking global investment opportunities. Our goal is to place $100 million in investments during the next 4-5 years, with an immediate emphasis on cardiovascular, central nervous system, metabolic and oncology therapeutic domains. The scope of the fund does not include diagnostics, devices, gene therapy or anti-infective products.

About TPC
Takeda Pharmaceutical Company Ltd., is a research-based global company with its main focus on pharmaceuticals. It is the largest pharmaceutical company in Japan and among the largest in the world. TPC is committed to striving toward better health for individuals and progress of medicine. It does this directly and also through joint ventures. Among the company's most notable successes to date are Actos®, Prevacid® (Takepron®), Lupron® (Enantone®), and Blopress® (Atacand®).

TPC takes pride in its highly regarded discovery research capabilities which continue to fuel an innovative pipeline of drug candidates in all areas where the medical need remains high. Through judicious investment in high-caliber biopharmaceutical and technology-based ventures, TRI aims to further increase the depth and breadth of these capabilities and ensure that Takeda remains a major force in the drive to improve global human healthcare.